US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AI Healthcare

619.81

+51.028.97%

Number of Gainers:4

Number of Losers:- -

Number of Flat:- -

PE:- -

High:626.14

Open:571.03

Low:571.03

Close:568.79

Loading ...

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip

Tempus AI announces expansion of Tempus One

Tempus AI announces launch of its Fuses program

BRIEF-Tempus Introduces Fuses, A Program Designed To Transform Therapeutic Research And Build The Largest Diagnostic Platform Using Its Novel Foundation Model

Tempus Introduces Fuses, a Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using Its Novel Foundation Model

THOMSON REUTERS

Tempus AI Unveils Groundbreaking Fuses Program to Revolutionize Diagnostic Platform and Enhance Personalized Medicine

New Hope for Strokes And Heart Attacks -- Barron's

CRISPR Therapeutics AG's Chief Medical Officer Naimish Patel Reports Disposal of Common Shares

Beam Therapeutics treatment of sickle cell disease granted orphan designation

Sector Update: Health Care Stocks Fall Pre-Bell Friday

MT Newswires Live

Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics today

Beam Therapeutics Says FDA Grants Orphan Drug Designation to Lung, Liver Treatment

Beam Therapeutics receives orphan drug designation for BEAM-302

Beam Therapeutics Inc - Initiates Dosing in Fourth Cohort, Data Expected in H2 2025

THOMSON REUTERS

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd)

THOMSON REUTERS

Beam Therapeutics Inc - to Dose First Patient in Part B of Trial in H2 2025

THOMSON REUTERS

Beam Therapeutics treatment of alpha-1 antitrypsin deficiency gets orphan status

A Cathie Wood Favorite Is Falling: Why Tempus AI Stock Is Imploding Today

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

Tempus AI Shares Extend Losses, Last Down 14.8%

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":619.81287,"timestamp":1749239999999,"preClose":568.7886,"halted":0,"volume":80607447,"delay":0,"changeRate":0.089707,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":51.024292,"latestTime":"06-06 16:00:00 EDT","open":571.0336,"high":626.13544,"low":571.0336,"amount":1306537605.096571,"amplitude":0.096876,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.036362,"peRate":-8.266372,"turnoverRate":0.121041,"increases":4,"decrements":0,"flats":0,"marketCap":18454890496,"floatMarketCap":13646941824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":626.13544,"amplitude":0.096876,"preClose":568.7886,"low":571.0336,"pbRate":"4.036362","latestPrice":619.81287,"volume":80607447,"delay":0,"open":571.0336,"prevYearClose":530.4984,"prevWeekClose":532.1039,"prevMonthClose":532.1039,"prevQuarterClose":527.803,"fiveDayClose":532.1039,"twentyDayClose":587.4983,"sixtyDayClose":594.3155,"secType":"PLATE","market":"US","turnoverRate":0.121041,"peRate":-8.266372,"marketCap":18454890496,"floatMarketCap":13646941824,"timestamp":1749239999999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":4,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540760986","title":"The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2540760986","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540760986?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:45","pubTimestamp":1748864700,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics has the potential to generate significant breakthroughs in gene editing.Regeneron's biggest growth driver is still performing well, and it is developing newer medicines.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/02/the-2-smartest-beaten-down-biotech-stocks-to-buy-o/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4534","LU0943347566.SGD","LU2756315664.SGD","BK4083","LU0820562030.AUD","LU0820561909.HKD","LU0320765646.SGD","LU0354030438.USD","LU1778281490.HKD","LU1861558580.USD","BK4504","LU1093756325.SGD","BK4581","LU0823411888.USD","LU1069344957.HKD","HD","LU1551013425.SGD","LU1989772840.SGD","LU0079474960.USD","BK4566","SCD","IE00B1XK9C88.USD","CRSP","LU0868494708.USD","LU0823434583.USD","IE00BWXC8680.SGD","BK4585","LU1551013342.USD","LU0823434740.USD","LU1496350502.SGD","BK4611","IE00BZ1G4Q59.USD","BK4588","LU1162221912.USD","LU1674673428.USD","SG9999001440.SGD","BK4567","BK4533","LU0868494617.USD","IE00BSNM7G36.USD","LU0689472784.USD","LU1861559042.SGD","BK4556","LU0354030511.USD","LU1989772923.USD","BK4139","LU1674673691.USD","LU2756315318.SGD","LU1496350171.SGD","LU0234572021.USD"],"gpt_icon":0},{"id":"2540730939","title":"Tempus AI announces expansion of Tempus One","url":"https://stock-news.laohu8.com/highlight/detail?id=2540730939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540730939?lang=en_us&edition=fundamental","pubTime":"2025-06-02 04:10","pubTimestamp":1748808604,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) announced the expansion of Tempus One-its generative AI clinical assistant-with direct integration into electronic health record, E...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-announces-expansion-of-tempus-one-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-announces-expansion-of-tempus-one-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","TEM","BK4611","BK4613","LU1861558580.USD","BK4121"],"gpt_icon":0},{"id":"2540303367","title":"Tempus AI announces launch of its Fuses program","url":"https://stock-news.laohu8.com/highlight/detail?id=2540303367","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540303367?lang=en_us&edition=fundamental","pubTime":"2025-06-02 03:55","pubTimestamp":1748807703,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary dataset to generate valuable insights f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-announces-launch-of-its-fuses-program-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-announces-launch-of-its-fuses-program-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4611","LU1861559042.SGD","BK4613","TEM","LU1861558580.USD"],"gpt_icon":0},{"id":"2539786202","title":"BRIEF-Tempus Introduces Fuses, A Program Designed To Transform Therapeutic Research And Build The Largest Diagnostic Platform Using Its Novel Foundation Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786202","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786202?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:30","pubTimestamp":1748694645,"startTime":"0","endTime":"0","summary":"BRIEF-Tempus Introduces Fuses, A Program Designed To Transform Therapeutic Research And Build The Largest Diagnostic Platform Using Its Novel Foundation ModelMay 31 (Reuters) - Tempus AI Inc TEM.O:TEM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nFWN3S3001:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","TEM","BK4121","BK4611","BK4613","LU1861559042.SGD"],"gpt_icon":1},{"id":"2539178620","title":"Tempus Introduces Fuses, a Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using Its Novel Foundation Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2539178620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539178620?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:30","pubTimestamp":1748694625,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nFWN3S3001:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861558580.USD","BK4613","TEM","LU1861559042.SGD","BK4611","BK4121"],"gpt_icon":0},{"id":"2539786204","title":"Tempus AI Unveils Groundbreaking Fuses Program to Revolutionize Diagnostic Platform and Enhance Personalized Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786204","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786204?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:30","pubTimestamp":1748694618,"startTime":"0","endTime":"0","summary":"Tempus AI Inc. has announced the launch of its Fuses program, a groundbreaking initiative aimed at transforming therapeutic research and building the largest diagnostic platform using its novel foundation model. Utilizing a massive, multimodal dataset containing over 40 million research records, Tempus aims to enhance diagnostic, prognostic, and predictive modeling. The Fuses program will leverage this extensive dataset to develop AI-driven diagnostics that offer personalized care solutions, such as identifying patients unlikely to respond to approved therapies or those at risk of severe treatment-related events. This initiative builds on Tempus' existing work, including the Immune Profile Score  launched last year, and positions the company to deliver significant advancements in precision medicine. Eric Lefkofsky, Founder and CEO of Tempus, emphasized the potential for transformative change in matching therapies to patients, moving toward the realization of personalized care for milli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nNDLbq8xy6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU1861559042.SGD","BK4613","TEM","BK4611","LU1861558580.USD"],"gpt_icon":1},{"id":"2539201896","title":"New Hope for Strokes And Heart Attacks -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2539201896","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539201896?lang=en_us&edition=fundamental","pubTime":"2025-05-31 09:30","pubTimestamp":1748655000,"startTime":"0","endTime":"0","summary":"Big Pharma, biotechs, and gene-editing specialists are developing a bevy of new cardiovascular drugs. How they could curb bypass surgeries. By Bill Alpert. Forty years after the first statin drug started lowering levels of artery-choking cholesterol, heart attacks and strokes remain the world's biggest killers. This year will see test results on some drugs that cut cholesterol even more.Statins are cheap and effective drugs for reducing blood levels of the \"bad\" cholesterol known as LDL, which gunks up arteries over time. A quarter of Americans have high LDL. But only about half of patients stay on their prescribed statins, and the drugs don't get LDL low enough in some 10% of patients.The cost and hassle has led to sales that are good, but not as great as expected. Regeneron and Sanofi's Praluent sales were $585 million in 2024. For the same year, Amgen's Repatha pulled in $2.2 billion, up 15% year over year. Last year's sales of Leqvio for Novartis were $260 million, up 80%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU1127390331.HKD","IE00BN8TJ469.HKD","LU2456880835.USD","IE0009355771.USD","LU1116320901.HKD","LU0708995401.HKD","LU1232071149.USD","LU2491050154.USD","SG9999015952.SGD","LU1974910355.USD","BK4611","BK4534","LU2237443895.HKD","SGXZ57979304.SGD","LU0320765646.SGD","LLY","BK4139","MRK","IE00BK4W5L77.USD","HOPE","LU0058720904.USD","LU0466842654.USD","LU0198837287.USD","BK4585","BK4516","IE00BLSP4452.SGD","LU1989772923.USD","SG9999002224.SGD","LU0266013472.USD","LU1066051498.USD","LU1829250122.USD","AMGN","LU0208291251.USD","LU0417517546.SGD","AZN","LU2211815571.USD","LU0097036916.USD","LU0106261372.USD","LU1116320737.USD","LU0320765992.SGD","LU2242646821.SGD","LU1934455194.USD","IE0004445239.USD","SG9999015341.SGD","LU1291159041.SGD","CRSP","LU0861579265.USD","LU2471134523.USD","LU2471134879.HKD"],"gpt_icon":1},{"id":"2539717208","title":"CRISPR Therapeutics AG's Chief Medical Officer Naimish Patel Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2539717208","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539717208?lang=en_us&edition=fundamental","pubTime":"2025-05-31 05:00","pubTimestamp":1748638848,"startTime":"0","endTime":"0","summary":"Naimish Patel, Chief Medical Officer, reported a disposal of common shares of CRISPR Therapeutics AG. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL7pzfcd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CRISPR Therapeutics AG's Chief Medical Officer Naimish Patel Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4588","BK4556","BK4585","CRSP","BK4611","BK4139","LU1861559042.SGD"],"gpt_icon":0},{"id":"2539277510","title":"Beam Therapeutics treatment of sickle cell disease granted orphan designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2539277510","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539277510?lang=en_us&edition=fundamental","pubTime":"2025-05-31 03:00","pubTimestamp":1748631615,"startTime":"0","endTime":"0","summary":"The FDA granted orphan designation to a treatment of sickle cell disease being developed by Beam Therapeutics (BEAM), according to a post to the ag...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-treatment-of-sickle-cell-disease-granted-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-treatment-of-sickle-cell-disease-granted-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4585","BK4139","BK4556","BK4535","BK4588","BK4007","BEAM","BK4539","BK4611","BK4505"],"gpt_icon":0},{"id":"2539220892","title":"Sector Update: Health Care Stocks Fall Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2539220892","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539220892?lang=en_us&edition=fundamental","pubTime":"2025-05-30 21:17","pubTimestamp":1748611073,"startTime":"0","endTime":"0","summary":"Health care stocks were falling pre-bell Friday as the Health Care Select Sector SPDR Fund  was down 0.4% and the iShares Biotechnology ETF  was 1.4% lower recently.Sanofi  and Regeneron Pharmaceuticals  said one of the phase 3 trials of itepekimab in adults who were former smokers with inadequately controlled chronic obstructive pulmonary disease, or COPD, met its primary endpoint while another did not meet the same primary endpoint. Shares of Sanofi were down more than 4% while Regeneron shares were more than 13% lower premarket.Cooper  shares were down more than 8% even after the company reported higher fiscal Q2 non-GAAP earnings and net sales.Beam Therapeutics  shares were advancing by more than 3% after the company said the US Food and Drug Administration granted orphan drug designation to BEAM-302.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN","LU0053666078.USD","LU2272731782.SGD","XLV","BK4139","LU0320765992.SGD","COO.AU","LU1917777945.USD","LU1974910355.USD","LU2211815571.USD","LU2362540622.SGD","BK4535","LU0289739699.SGD","LU0823434583.USD","LU0889565916.HKD","LU0114720955.EUR","BK4556","LU0823416689.USD","BK4007","LU1992135399.USD","LU0109394709.USD","LU1992135472.HKD","LU0058720904.USD","BEAM","SNY","IBB","IE00BFXG1179.USD","BK4588","LU0823434740.USD","BK4585","GB00BDT5M118.USD","LU2023250504.SGD","LU2106854487.HKD","BK4581","COO","LU2089984988.USD","LU2468319806.SGD","BK7016","BK4198","LU0882574055.USD","LU2362541273.HKD","LU2237438978.USD","LU2362541513.USD","BK4505","LU2272731600.USD","BK4611"],"gpt_icon":0},{"id":"2539290300","title":"Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2539290300","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539290300?lang=en_us&edition=fundamental","pubTime":"2025-05-30 08:50","pubTimestamp":1748566214,"startTime":"0","endTime":"0","summary":"20:48 EDT Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ultimate source for rea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-294k-shares-of-crispr-therapeutics-today-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-294k-shares-of-crispr-therapeutics-today-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRSP","ARKK","LENZ","BK4611","BK4539","BK4556","BK4588","LU1861559042.SGD","LU1861558580.USD","BK4139","BK4585","BK4007","BK4544"],"gpt_icon":0},{"id":"2539299256","title":"Beam Therapeutics Says FDA Grants Orphan Drug Designation to Lung, Liver Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2539299256","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539299256?lang=en_us&edition=fundamental","pubTime":"2025-05-30 05:51","pubTimestamp":1748555460,"startTime":"0","endTime":"0","summary":"Beam Therapeutics said the Food and Drug Administration has granted an orphan drug designation to its treatment for a genetic disorder that affects the lungs and or liver.The Cambridge, Mass.-based biotechnology company's drug, BEAM-302, is a liver-targeting lipid nanoparticle formulation that is designed to correct for a mutation in patients with alpha-1 antitrypsin deficiency. AATD, an inherited genetic disorder, leads to early onset emphysema and liver disease.The FDA's orphan drug designation is to support the development and evaluation of treatments for rare diseases that affect fewer than 200,000 people. It includes benefits such as exemption from user fees and seven years of market exclusivity after approval.\"Receiving orphan drug designation for BEAM-302 is an important milestone in our efforts to bring a transformative therapy to people living with AATD, many of whom currently lack effective long-term treatment options,\" said Beam Therapeutics' President Giuseppe Ciaramella.Th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BEAM","LENZ","BK4505","BK4611","BK4007","BK4535","BK4139","BK4588","BK4556","BK4585"],"gpt_icon":0},{"id":"2539229559","title":"Beam Therapeutics receives orphan drug designation for BEAM-302","url":"https://stock-news.laohu8.com/highlight/detail?id=2539229559","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539229559?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:11","pubTimestamp":1748549513,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) announced that the FDA has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle formulation o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-receives-orphan-drug-designation-for-beam-302-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-receives-orphan-drug-designation-for-beam-302-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BEAM","BK4556","BK4139","BK4505","BK4585","BK4611","BK4588"],"gpt_icon":0},{"id":"2539429310","title":"Beam Therapeutics Inc - Initiates Dosing in Fourth Cohort, Data Expected in H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539429310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539429310?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:01","pubTimestamp":1748548860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA4BDGVK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4611","BEAM","BK4535","BK4505","BK4585","BK4556","BK4139"],"gpt_icon":0},{"id":"2539293103","title":"Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2539293103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539293103?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:01","pubTimestamp":1748548860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA4BDGVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","BK4556","BK4505","BK4535","BK4585","BEAM","BK4588","BK4139"],"gpt_icon":0},{"id":"2539101293","title":"Beam Therapeutics Inc - to Dose First Patient in Part B of Trial in H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539101293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539101293?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:01","pubTimestamp":1748548860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA4BDGVK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4611","BK4585","BK4535","BK4588","BK4556","BEAM","BK4505"],"gpt_icon":0},{"id":"2539981402","title":"Beam Therapeutics treatment of alpha-1 antitrypsin deficiency gets orphan status","url":"https://stock-news.laohu8.com/highlight/detail?id=2539981402","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539981402?lang=en_us&edition=fundamental","pubTime":"2025-05-29 06:10","pubTimestamp":1748470210,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM)’ treatment of alpha-1 antitrypsin deficiency was granted FDA orphan designation status, according to a post to the agency’...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-treatment-of-alpha-1-antitrypsin-deficiency-gets-orphan-status-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-treatment-of-alpha-1-antitrypsin-deficiency-gets-orphan-status-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4535","BEAM","BK4556","BK4539","LENZ","BK4007","BK4611","BK4139","BK4585","BK4505"],"gpt_icon":0},{"id":"2539405611","title":"A Cathie Wood Favorite Is Falling: Why Tempus AI Stock Is Imploding Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2539405611","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539405611?lang=en_us&edition=fundamental","pubTime":"2025-05-29 02:32","pubTimestamp":1748457120,"startTime":"0","endTime":"0","summary":"One of Cathie Wood's largest holdings, Tempus AI, was targeted by a short-seller.The report, released today, alleges Tempus is misleading investors about its use of artificial intelligence , as well as other questionable practices.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/28/a-cathie-wood-favorite-is-falling-why-tempus-ai-st/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["ARKK","BK4121","BK4613","LU1861558580.USD","BK4611","TEM","LU1861559042.SGD"],"gpt_icon":1},{"id":"2539940306","title":"Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2539940306","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539940306?lang=en_us&edition=fundamental","pubTime":"2025-05-29 02:06","pubTimestamp":1748455560,"startTime":"0","endTime":"0","summary":"Forty years after the first statin drug started lowering levels of artery-choking cholesterol, heart attacks and strokes remain the world's biggest killers. This year will see test results on some drugs that cut cholesterol even more.Statins are cheap and effective drugs for reducing blood levels of the \"bad\" cholesterol known as LDL, which gunks up arteries over time. A quarter of Americans have high LDL. But only about half of patients stay on their prescribed statins, and the drugs don't get LDL low enough in some 10% of patients.\"Even with everything that we've done in the field, there is actually a fair amount of new things in the pipeline,\" said researcher Steve Nissen, a cardiologist at the Cleveland Clinic who conducts clinical trials on many of the new drugs.To address these drugs' cost and convenience issues, Merck is testing a pill treatment that it code-named MK-0616. The company is b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","BK4559","LU0320765992.SGD","LU1551013342.USD","AMGN","LU0466842654.USD","LU2602419157.SGD","BK4556","LU1988902786.USD","LU0689472784.USD","LU1934455863.HKD","SG9999001176.SGD","LU0234572021.USD","BK4566","LU1066053197.SGD","AZN","IE00B2B36J28.USD","LU0203202063.USD","LU2237443895.HKD","IE00B1BXHZ80.USD","LU1934455277.USD","LU2237443622.USD","SG9999014880.SGD","BK4611","IE00BSNM7G36.USD","LU2468319806.SGD","SG9999014906.USD","LU0708995401.HKD","LU1814569148.SGD","LU1861558580.USD","LU1035775433.USD","LU2471134523.USD","LU1941712264.USD","LLY","SG9999018857.SGD","LU0786609619.USD","LU2063271972.USD","BK4139","LU1623119135.USD","CRSP","LU0096364046.USD","SGXZ31699556.SGD","LU1804176565.USD","IE0004445239.USD","LU0354030438.USD","LU1989771016.USD","MRK","LU0079474960.USD","LU1720051017.SGD","LU2491050071.SGD"],"gpt_icon":1},{"id":"2538247786","title":"Tempus AI Shares Extend Losses, Last Down 14.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2538247786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538247786?lang=en_us&edition=fundamental","pubTime":"2025-05-28 23:07","pubTimestamp":1748444833,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5a1f935a527245ffb5153fe5b9fa56eb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nL3N3S016R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","LU1861558580.USD","TEM","BK4613","BK4121","LU1861559042.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}]}}